Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy

Growing clinical evidence has implicated complement as a pivotal driver of COVID-19 immunopathology. Deregulated complement activation may fuel cytokine-driven hyper-inflammation, thrombotic microangiopathy and NET-driven immunothrombosis, thereby leading to multi-organ failure. Complement therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastellos, Dimitrios C., Pires da Silva, Bruno G.P., Fonseca, Benedito A.L., Fonseca, Natasha P., Auxiliadora-Martins, Maria, Mastaglio, Sara, Ruggeri, Annalisa, Sironi, Marina, Radermacher, Peter, Chrysanthopoulou, Akrivi, Skendros, Panagiotis, Ritis, Konstantinos, Manfra, Ilenia, Iacobelli, Simona, Huber-Lang, Markus, Nilsson, Bo, Yancopoulou, Despina, Connolly, E. Sander, Garlanda, Cecilia, Ciceri, Fabio, Risitano, Antonio M., Calado, Rodrigo T., Lambris, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501834/
https://www.ncbi.nlm.nih.gov/pubmed/32961333
http://dx.doi.org/10.1016/j.clim.2020.108598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501834/
https://www.ncbi.nlm.nih.gov/pubmed/32961333
http://dx.doi.org/10.1016/j.clim.2020.108598

Ejemplares similares